Perjeta, also known as pertuzumab, represents a crucial advancement in addressing HER2-positive certain types of cancer. It works by inhibiting a specific pathway which helps cancer cells multiply . Differing from some alternative HER2-targeted therapies, pertuzumab avoids directly block the HER2